Rodman & Renshaw Sees 243% Upside In OncoSec Medical Shares
Rodman & Renshaw initiated coverage on OncoSec Medical Inc (NASDAQ: ONCS) with a Buy rating and $6.00 price target, describing the company as representing a unique opportunity in the oncology sector, positioned in the highly visible and widely-followed immunotherapy domain.
According to the analysts, several near-term value drivers could constitute meaningful upside to their estimates. "We currently only model sales of ImmunoPulse™ IL-12 in melanoma, without factoring in contributions from other potential therapeutic candidates generated by OncoSec's proprietary technology platform or possible applications in other indications, such as triple-negative breast cancer (TNBC)," the analysts wrote.
They also mentioned three major risks to their valuation, including (1) negative trial data, (2) failure to show synergy with approved immunotherapy drugs, (3) regulatory delays or rejections.
Did you like this article? Could it have been improved? Please email email@example.com with the story link to let us know!
Latest Ratings for ONCS
|Jul 2016||Rodman & Renshaw||Assumes||Buy|
|Mar 2016||H.C. Wainwright||Maintains||Buy|
|Jun 2015||H.C. Wainwright||Assumes||Buy|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.